DOCK1 and gastric cancer: Moreover, Dock180 rs4635002 and C3G rs7853122 showed significantly decreased risk of gastric cancer in both analyses (OR = 0.60, [95% CI: 0.42–0.84], OR = 0.61, [95% CI: 0.43–0.87] for Dock180 rs4635002; OR = 0.59, [95% CI: 0.45–0.77], OR = 0.59, [95% CI: 0.45–0.76] for C3G rs7853122).